NCT05400967View on ClinicalTrials.gov

Diagnosis of Metastatic Tumors on 68Ga-FAPI PET-CT and Radioligand Therapy with 177Lu-EB-FAPI

EARLY_PHASE1RecruitingINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

January 1, 2022

Primary Completion Date

January 1, 2025

Study Completion Date

April 1, 2025

Conditions
177Lu-EB-FAPI
Interventions
DRUG

68Ga-FAPI for PET / CT scan and 177Lu-EB-FAPI for therapy

Patients with positive results were screened with 68Ga-FAPI PET / CT, and 2.22GBq(60mci) 177Lu-EB-FAPI was injected intravenously for therapy after contraindications were excluded and informed consent was signed.

Trial Locations (1)

100730

RECRUITING

Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing

All Listed Sponsors
lead

Peking Union Medical College Hospital

OTHER